AZ, Abbott dump heart drug

Following up on the FDA's decision to spurn the experimental heart drug Certriad back in March, Abbott and AstraZeneca announced that they were dumping the program. Regulators had asked for more data on the drug but the pharma companies said that the delay would kill the drug's market potential. This is AZ's third setback in the past week. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.